Curated News
By: NewsRamp Editorial Staff
October 20, 2026
Quantum BioPharma's Unbuzzd Shines in Men's Fitness Trial Review
TLDR
- Quantum BioPharma's Unbuzzd showed a 40.7% greater blood alcohol decline in rapid responders, giving it a potential edge in the alcohol recovery market.
- The placebo-controlled study involved 26 adults, with 24 completing both sessions, and measured estimated blood alcohol concentrations and self-rated alertness at multiple time points.
- Quantum BioPharma's Unbuzzd may improve alcohol recovery by reducing blood alcohol and headaches, potentially making recovery easier for individuals.
- In a small trial, Unbuzzd cut estimated blood alcohol by 40.7% more than placebo in the first 30 minutes for 17 rapid responders.
Impact - Why it Matters
The Men’s Fitness article elevates public awareness of Unbuzzd and its potential to address alcohol recovery, a market with significant consumer interest. For Quantum BioPharma, positive coverage could enhance brand credibility and attract investor attention, though the study’s limitations underscore the need for robust, independent research. As alcohol consumption remains widespread, products that mitigate its aftereffects could have substantial public health and commercial implications. However, consumers should interpret these early findings cautiously and await further clinical validation.
Summary
Quantum BioPharma (NASDAQ: QNTM) is drawing attention after being featured in a Men’s Fitness article by Lakshan Weeraratne that examines clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article details a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness, and reduced headache severity on certain assessments. Notably, among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. These findings suggest that Unbuzzd may accelerate alcohol metabolism and alleviate some hangover symptoms, though the article emphasizes the need for further validation.
The Men’s Fitness coverage also highlights important limitations of the study, including its small sample size, company sponsorship, and mixed results across broader measures of hangover severity and cognitive impairment. While the findings point to potential benefits for certain alcohol recovery measures, the article notes that larger, independent clinical trials are needed to confirm the results. It also cautions that increased alertness does not indicate sobriety or fitness to drive. Quantum BioPharma, a biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and metabolic disorders and alcohol misuse, retains a 19.84% ownership stake in Unbuzzd and receives a 7% royalty on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also owns 100% of the rights to develop similar products for pharmaceutical and medical uses.
For investors and consumers, the Men’s Fitness feature brings added visibility to Quantum’s Unbuzzd and its potential in the alcohol recovery market. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and full terms of use and disclaimers can be found on the InvestorBrandNetwork website. As research progresses, the outcomes of larger trials will be critical in determining whether Unbuzzd can become a trusted solution for alcohol recovery.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma's Unbuzzd Shines in Men's Fitness Trial Review
